Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
An. pediatr. (2003. Ed. impr.) ; 100(2): 115-122, Feb. 2024. ilus, tab, graf
Artigo em Espanhol | IBECS | ID: ibc-230285

RESUMO

Introducción: El hidrops fetal (HF) es una condición rara con una alta mortalidad. Este estudio analiza la evolución obstétrica y perinatal de los diagnósticos prenatales de HF, relacionándola con la etiología y el tratamiento intrauterino (TIU) recibido. Pacientes y métodos: Se revisaron 164 gestantes con diagnóstico prenatal de HF entre 2011 y 2021. Se registraron intervenciones prenatales, hallazgos clínicos, etiologías y resultados de los recién nacidos vivos. Resultados: Se realizó un estudio invasivo prenatal en el 79,3% de los pacientes. Las etiologías mayoritarias fueron alteraciones genéticas (31%), infecciones TORCH y por parvovirus B19 (9,7%), y cardiopatías estructurales (9,1%). En el 25,6% se realizó TIU, y entre todas las gestaciones, el 74,4% fueron interrumpidas. Las alteraciones genéticas tuvieron tasas más altas de interrupción legal del embarazo respecto a otras etiologías (p<0,01). Del total, solo nacieron el 25,6% de los fetos, la mayoría pretérmino. Los que recibieron TIU gozaron de mayores tasas de supervivencia perinatal y al año de vida (p<0,001). De entre aquellos nacimientos, las cardiopatías estructurales presentaron las peores tasas de supervivencia, mientras que las causas con mejor pronóstico fueron las taquiarritmias. La supervivencia al año de vida entre aquellos recién nacidos vivos fue del 70%, pero el 58,6% asociaron morbilidad significativa al alta. Conclusiones: A pesar de los avances en el manejo del HF, el mal pronóstico obstétrico, la mortalidad perinatal y la morbilidad de los supervivientes siguen siendo significativos. Estos datos son importantes para asesorar a las familias que reciben un diagnóstico prenatal de HF.(AU)


Introduction: Hydrops fetalis (HF) is a rare condition with a high mortality. This study analysed the obstetric and perinatal outcomes of antenatally diagnosed HF according to its aetiology and the possibility of intrauterine treatment (IUT). Patients and methods: We carried out a retrospective review of the health records of 164 pregnant women with a prenatal diagnosis of HF in a tertiary care centre between 2011 and 2021. We analysed prenatal interventions, clinical findings, aetiologies and obstetric and live-born infant outcomes. Results: An invasive prenatal study had been performed in 79.3% cases. The most common aetiologies were genetic disorders (31%), TORCH and parvovirus B19 infections (9.7%) and structural heart diseases (9.1%). Intrauterine treatment was performed in 25.6%, and 74.4% of pregnancies were terminated. Pregnancies with a prenatal diagnosis of genetic or chromosomal disorders had higher rates of elective termination compared to other aetiologies (P<.01). Among all pregnancies, only 25.6% resulted in live births (LBs), most of them preterm. Perinatal and 1-year survival rates were higher in the group that received IUT (P<.001). Among the LBs, structural heart diseases had the worst survival rates, while the aetiology with the best outcomes was tachyarrhythmia. Survival at 1year of life among those born alive was 70%, but 58.6% of these infants had significant morbidity at discharge. Conclusions: Despite advances in the management of FH, the poor obstetric prognosis, perinatal mortality and morbidity of survivors is still significant. These data are important for the purpose of counselling families when HF is diagnosed antenatally.(AU)


Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Diagnóstico Pré-Natal , Hidropisia Fetal/mortalidade , Parvovirus B19 Humano , Complicações na Gravidez , Dispositivos Intrauterinos , Pediatria , Doenças do Recém-Nascido , Neonatologia , Estudos Retrospectivos , Obstetrícia
2.
An Pediatr (Engl Ed) ; 100(2): 115-122, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38307752

RESUMO

INTRODUCTION: Hydrops fetalis (HF) is a rare condition with a high mortality. This study analysed the obstetric and perinatal outcomes of antenatally diagnosed HF according to its aetiology and the possibility of intrauterine treatment (IUT). PATIENTS AND METHODS: We carried out a retrospective review of the health records of 164 pregnant women with a prenatal diagnosis of HF in a tertiary care centre between 2011-2021. We analysed prenatal interventions, clinical findings, aetiologies and obstetric and live-born infant outcomes. RESULTS: An invasive prenatal study had been performed in 79.3% cases. The most common aetiologies were genetic disorders (31%), TORCH and parvovirus B19 infections (9.7%) and structural heart diseases (9.1%). Intrauterine treatment was performed in 25.6%, and 74.4% of pregnancies were terminated. Pregnancies with a prenatal diagnosis of genetic or chromosomal disorders had higher rates of elective termination compared to other aetiologies (P < .01). Among all pregnancies, only 25.6% resulted in live births (LBs), most of them preterm. Perinatal and 1-year survival rates were higher in the group that received IUT (P < .001). Among the LBs, structural heart diseases had the worst survival rates, while the aetiology with the best outcomes was tachyarrhythmia. Survival at 1 year of life among those born alive was 70%, but 58.6% of these infants had significant morbidity at discharge. CONCLUSIONS: Despite advances in the management of FH, the poor obstetric prognosis, perinatal mortality and morbidity of survivors is still significant. These data are important for the purpose of counselling families when HF is diagnosed antenatally.


Assuntos
Cardiopatias , Hidropisia Fetal , Recém-Nascido , Humanos , Gravidez , Feminino , Hidropisia Fetal/diagnóstico , Hidropisia Fetal/etiologia , Hidropisia Fetal/terapia , Centros de Atenção Terciária , Diagnóstico Pré-Natal , Estudos Retrospectivos , Cardiopatias/complicações
3.
Prog. obstet. ginecol. (Ed. impr.) ; 53(4): 163-166, abr. 2010. tab
Artigo em Espanhol | IBECS | ID: ibc-79133

RESUMO

Objetivo: Demostrar la utilidad del taponamiento mecánico del útero con balón en el tratamiento de la hemorragia posparto. Material y métodos: 5 gestantes a término, tratadas por hemorragia posparto precoz. El criterio para colocar el balón fue el sangrado persistente a pesar del tratamiento farmacológico. Resultados: La colocación del balón fue exitosa en el 100% de los casos. El descenso medio de hemoglobina fue de 3,2g/dl (rango [r]=1-5) y se requirió una media de 3 concentrados de hematíes por paciente (r=0-6). El volumen medio de suero por balón fue de 312ml (r=160-420) y el tiempo medio de tratamiento fue de 22h (r=: 12-30). Conclusiones: El taponamiento uterino con balón constituye un método eficiente para el control de la hemorragia uterina posparto. Su aplicación no precisa entrenamiento y puede evitar la cirugía. Por su fácil manejo y coste asequible, es aplicable en cualquier medio hospitalario (AU)


Objective: To demonstrate the usefulness of uterine balloon tamponade in postpartum hemorrhage. Material and methods: Five term pregnancies with postpartum hemorrhage were studied. The criterion for balloon placement was persistent bleeding despite pharmacological treatment. Results: Balloon placement was successful in 100% of the patients. The mean decrease in hemoglobin was 3.2g/dl (range: 1-5) and an average of three units of packed red blood cells per patient were required (range: 0-6). The mean volume of saline solution per balloon was 312ml (range: 160-420) and the mean duration of treatment was 22hours (range: 12-30). Conclusions: Uterine balloon tamponade is an efficient method to control postpartum hemorrhage. Training is not required for the application of this technique, which can obviate the need for surgery. Because of its ease of use and reasonable cost, this method can be used in any hospital setting (AU)


Assuntos
Humanos , Feminino , Gravidez , Adulto , Hemorragia Uterina/complicações , Hemorragia Uterina/diagnóstico , Hemorragia Uterina/terapia , Oclusão com Balão/métodos , Hemostasia/fisiologia , Metilergonovina/uso terapêutico , Ocitocina/uso terapêutico , Misoprostol/uso terapêutico , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/terapia , Esclerose Múltipla/complicações , Cateterismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...